NVP-2 | CDK9 inhibitor
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $85.00 | ||
| 25 mg | $295.00 |
NVP-2 (1263373-43-8) is a highly selective and potent (IC50 = 0.514 nM) inhibitor of cyclin dependent kinase 9 (CDK9).1 It inhibited proliferation of MOLT4 cells (IC50 = 9 nM). Treatment of cells with NVP-2 resulted in profound downregulation of core regulatory circuitry genes. It has also been shown to be a potent inhibitor of CDK10 (IC50 = 29 nM; this study gives an IC50 of 6 nM for CDK9).2 NVP-2 acted synergistically with orlistat to inhibit acute myeloid leukemia cells (IC50s: Kasumi-1 cells 7.58 nM; U937 cells 8.99 nM).3
References/Citations:
- Olson et al. (2018), Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation; Nat. Chem. Biol. 14 163
- Robert et al. (2020); Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors, Front. Chem., 8 147
- Zhu et al. (2025), NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia; Cancer Biol. Ther. 26 2450859
C27H37ClN6O2
>98% HPLC
NMR: (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
NVP-2 (1263373-43-8) is a highly selective and potent (IC50 = 0.514 nM) inhibitor of cyclin dependent kinase 9 (CDK9).1 It inhibited proliferation of MOLT4 cells (IC50 = 9 nM). Treatment of cells with NVP-2 resulted in profound downregulation of core regulatory circuitry genes. It has also been shown to be a potent inhibitor of CDK10 (IC50 = 29 nM; this study gives an IC50 of 6 nM for CDK9).2 NVP-2 acted synergistically with orlistat to inhibit acute myeloid leukemia cells (IC50s: Kasumi-1 cells 7.58 nM; U937 cells 8.99 nM).3
References/Citations:
- Olson et al. (2018), Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation; Nat. Chem. Biol. 14 163
- Robert et al. (2020); Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors, Front. Chem., 8 147
- Zhu et al. (2025), NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia; Cancer Biol. Ther. 26 2450859
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
Focus Biomolecules • Plymouth Meeting, PA USA • 1-855-FOCUS21
Focus Biomolecules
Plymouth Meeting, PA USA
1-855-FOCUS21
Website Created by Advanta Advertising LLC.